May 5, 2023

Lutetium-PSMA for Metastatic Prostate Cancer (Podcast)

FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Last year, the FDA approved lutetium prostate-specific membrane antigen (PSMA), a promising new therapy for managing metastatic castrate-resistant prostate cancer.

“There are a couple of other different treatments [after frontline therapies], but once we get past one or two treatments, the options become more and more limited,” says Christopher Wee, MD, a physician in the Genitourinary Medical Oncology Program at Taussig Cancer Center. “Lutetium-PSMA offers an option and is currently FDA-approved for people who have prostate cancer that has had progression on antigen receptor or a novel hormonal agent, as well as a taxane-based chemotherapy.”

In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Wee discusses standard of care for metastatic prostate cancer and the potential role of Lutetium-PSMA. He explores:

Advertisement
  • Treatment options, including hormonal therapy, chemotherapy and radioligand therapy
  • Trials and data that support the use of lutetium
  • Patient criteria and indications for lutetium-PSMA
  • A comparison of the radioactive compounds radium and lutetium-PSMA
  • Potential sequencing of lutetium for patients with metastatic disease
  • The future direction in the field of metastatic disease treatment

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Cancer Advances episodes at clevelandclinic.org/podcasts/cancer-advances or wherever you get your podcasts.

Excerpt from the podcast

Podcast host Dale Shepard, MD, PhD: Tell me about clinical trials that you are interested in with lutetium.

Dr. Wee: So, we know that this is a very effective and good option for men with castrate-resistant prostate cancer. Now we’re trying to start with the intensification in earlier line therapy – the idea that, you get your best shot at getting a meaningful response and prolonged response if you intensify therapy up front. You don’t want to save therapies for later lines because you don’t know what shape the patient will be in at that point.

We’ve seen this in a number of ways. One, we’ve seen the move from androgen deprivation alone to androgen deprivation therapy [ADT] plus one of these novel hormonal agents – apalutamide, abiraterone, enzalutamide. In the past year we’ve seen the argument some people have made for triplet therapy – both from PEACE-1 and ARASENS – demonstrating that ADT plus docetaxel, plus darolutamide in ARASENS was superior to ADT plus docetaxel.

Advertisement

So now currently, we’re testing in a clinical trial here at Cleveland Clinic for men that have newly diagnosed metastatic hormone sensitive prostate cancer that have PSMA avid disease on a PET scan. They can be randomized in a one-to-one fashion of standard of care. So, ADT plus abiraterone, enzalutamide or apalutamide, or standard of care plus lutetium.

This is very attractive because the control arm is standard of care. You’re getting what you would have been recommended anyway. And furthermore, if you’re randomized to the standard of care arm and you have progression of the disease, the protocol allows for crossover at that point to lutetium, which is currently not the option because a patient would have to have progression on chemotherapy as the label currently stands.

Related Articles

adverse events from immune checkpoint inhibitors
December 21, 2023
Managing Hormone Dysfunction-Related Adverse Events of Immunotherapy for Breast Cancer Treatment

Timing and type of side effects differ greatly from chemotherapy

23-CNR-4274330-CQD-Hero-650×450
October 18, 2023
Cleveland Clinic Lerner Research Institute to Host Head & Neck Cancer CME Symposium

Sessions explore treatment advances and multidisciplinary care

23-CNR-4210971-CQD-Hero-650×450 Dr Yu
October 9, 2023
Pathway Cross-Talk Suggests New Approach to Glioblastoma Treatment

New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues

23-CNR-4071967-CQD-Hero-650×450 scan for triple-negative breast cancer case study
September 19, 2023
Patient With Stage 4 Triple-Negative Breast Cancer in Remission 10 Years After Initial Diagnosis

Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations

23-CNR-4140381-CQD-Hero-650×450 eye toxicities in cancer treatment
September 7, 2023
Eye Toxicities More Prevalent Side Effect of Cancer Treatment Than Previously Understood

Early communication between oncologists and ophthalmologist warranted

23-CNR-4185077-CQD-Hero-650×450
August 31, 2023
CME Program Takes Multidisciplinary Approach to Colorectal Cancer

Case-based course delves into latest treatment approaches

outreach to underserved communities
June 2, 2023
Focus Groups Amplify the Voices of Black Congregants about Disparities in Clinical Trials

Long-term relationship building and engagement key to gaining community trust

Ad